EPO Risks May Now Outweigh Benefits In Cancer Patients, FDA Documents Say
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA briefing documents for May 10 Oncologic Drugs Advisory Committee meeting say evidence about the risks of mortality and tumors from use of erythropoiesis-stimulating agents has grown, while the products’ main benefit – reducing blood transfusions – is no longer as important as it once was.
You may also be interested in...
The Future Of ESAs – Is It All CKD Now?
Takeda and Affymax revise Hematide program to stop development for chemotherapy-induced anemia and focus on anemia related to chronic kidney disease.
The Future Of ESAs – Is It All CKD Now?
Takeda and Affymax revise Hematide program to stop development for chemotherapy-induced anemia and focus on anemia related to chronic kidney disease.
ESAs Increase Risk Of Death Among Cancer Patients, JAMA Article Suggests
Data from recent Phase III studies provide mortality signal previously unseen in analyses of the anemia therapies.